Mechanistic Insights Into Statin Chemoprevention Against MASLD-Associated Hepatocellular Carcinoma

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Hepatology Communications. Ovid https://doi.org/10.1097/HC9.0000000000001015 
Dr. Courtney L. Labrecque et al.

Points

UCLA investigators used single nucleus RNA sequencing to identify specialized hepatic stellate cells surrounding metabolic dysfunction associated steatotic liver disease tumors with elevated YAP signaling.
Laboratory experiments showed that statin administration depleted intracellular geranylgeranyl pyrophosphate levels, disrupting Rho GTPase protein prenylation and cytoskeletal structure within human hepatic stellate cells.
Reduced geranylgeranyl pyrophosphate forced the oncogenic transcriptional regulator YAP to remain outside the nucleus, preventing activation of genes involved in tissue remodeling.
Supplementing treated liver cells with exogenous geranylgeranyl pyrophosphate successfully reversed statin effects, proving the essential role of the GGPP Rho YAP signaling axis.
Increased expression of geranylgeranyl diphosphate synthase near liver tumors suggested that cancer cells secrete molecules influencing surrounding stellate cells, revealing new targets for chemoprevention.

Summary

This study evaluated the cellular mechanisms by which statins exert chemopreventive effects against hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Led by Dr. Jihane Benhammou at the David Geffen School of Medicine at UCLA and published in Hepatology Communications, the investigation focused on hepatic stellate cell (HSC) subpopulations surrounding MASLD-related liver tumors. The research sought to define how local tumor microenvironment signaling promotes oncogenic remodeling and whether statin therapy suppresses these pathobiological pathways independent of systemic cholesterol reduction.

Using single-nucleus RNA sequencing and spatial imaging on resected or transplanted human liver tissue, researchers identified a specific population of tumor-associated HSCs (HCC-HSCs) characterized by selective upregulation of Yes-associated protein (YAP) effector genes. Mechanistic in vitro assays demonstrated that statins deplete intracellular geranylgeranyl pyrophosphate (GGPP), leading to reduced prenylation of Rho GTPases and altered cytoskeletal architecture. Consequently, YAP was retained in the cytoplasm rather than translocating to the cell nucleus, suppressing transcriptional activation of genes driving extracellular matrix remodeling and tissue fibrosis.

Experimental restoration of exogenous GGPP completely reversed statin-induced YAP cytosolic retention and gene suppression, confirming the centrality of the GGPP-Rho-YAP signaling axis. Additionally, spatial transcriptomics revealed elevated expression of GGPS1, the enzyme synthesizing GGPP, in peritumoral hepatocytes, suggesting potential metabolic crosstalk between tumor cells and adjacent HSCs. The authors conclude that statins target a distinct GGPP-dependent pathway in hepatic stellate cells, providing a mechanistically distinct chemoprotective rationale that warrants further investigation into targeted liver cancer prevention strategies for patients with MASLD.

Link to the article: https://www.ovid.com/jnls/hepcomm/fulltext/10.1097/hc9.0000000000001015~hepatic-stellate-cell-subpopulations-in-human-masld-related

References

Labrecque , C., Ko, A., Qiao, B., & Pan, C. (n.d.). Hepatic stellate cell subpopulations in human...: Hepatology Communications. Ovid. https://doi.org/10.1097/HC9.0000000000001015